Powered by

Innovent Announces Results Of TYVYT In Treatment Of Locally Advanced Or Metastat…

Jun 01, 2020 - Nasdaq

(RTTNews) - Innovent Biologics Inc. and Eli Lilly and Co. (LLY) announced the results of TYVYT or sintilimab injection ORIENT-2 study, a pivotal clinical study of second-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma or ESCC. The ORIENT-2 study was a randomized, open-label, multicenter, Phase 2 clinical study comparing the efficacy and safety of sintilimab with chemotherapy (paclitaxel or irinotecan) in patients with advanced or metastatic ESCC whose diseas...